GeneDx Holdings Corp. (WGS) stock
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$47.29−3.73 (-7.31%)
Close on Nov 17, 2026Market cap $1.41BP/E –Yield –
GeneDx operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
GeneDx's operating income for the twelve months ending Jun 30, 2026 was -$92.41M, down 1800.3% year over year. For fiscal 2025 it was -$13.08M. The highest annual figure on record is -$13.08M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.08M | – |
| FY2024 | Dec 31, 2024 | -$23.21M | – |
| FY2023 | Dec 31, 2023 | -$180.60M | – |
| FY2022 | Dec 31, 2022 | -$667.65M | – |
| FY2021 | Dec 31, 2021 | -$446.15M | – |
| FY2020 | Dec 31, 2020 | -$241.99M | – |
| FY2019 | Dec 31, 2019 | -$30.41M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.46M | -294.8% |
| Q1 FY2026 | Mar 31, 2026 | -$57.47M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.24M | -261.7% |
| Q3 FY2025 | Sep 30, 2025 | -$3.25M | – |
| Q2 FY2025 | Jun 30, 2025 | $8.96M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.55M | – |
| Q4 FY2024 | Dec 31, 2024 | $8.81M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.64M | – |
| Q3 FY2023 | Sep 30, 2023 | -$42.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$51.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$60.36M | – |
| Q4 FY2022 | Dec 31, 2022 | -$324.88M | – |
| Q3 FY2022 | Sep 30, 2022 | -$90.82M | – |
| Q2 FY2022 | Jun 30, 2022 | -$162.65M | – |
| Q1 FY2022 | Mar 31, 2022 | -$89.31M | – |
| Q4 FY2021 | Dec 31, 2021 | -$115.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$88.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$45.45M | – |
| Q1 FY2021 | Mar 31, 2021 | -$196.66M | – |
| Q4 FY2020 | Dec 31, 2020 | -$125.05M | – |
| Q3 FY2020 | Sep 30, 2020 | -$56.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$34.16M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.77M | – |
See a number that looks wrong?